SOUTH SAN FRANCISCO, CA, June 18 /CNW/ - Synosia Therapeutics today
announced that it has appointed Michael S. Eison, Ph.D., as the company's new
vice president of regulatory affairs, effective immediately.
Dr. Eison is an experienced drug developer and a seasoned veteran of
regulatory affairs. He spent the first 15 years of his career in central
nervous system (CNS) drug discovery/science management and the subsequent 11
years in regulatory affairs, formulating regulatory strategies that anticipate
the needs of the marketplace as well as those of worldwide health authorities.
"Michael Eison brings a depth of experience in CNS that enhances our
already solid capabilities in that area," said Synosia Chief Executive Officer
and President Ian Massey, "and the addition of his regulatory experience
certainly improves our ability to successfully navigate the regulatory
processes for CNS drug development."
Most recently, Eison was vice president of research and development for
the Palo Alto site of Stiefel Laboratories, but the majority of his career was
with the Bristol-Myers Squibb Company. He joined them as a scientist in 1981
and ultimately became the director of CNS drug discovery before changing
career direction and becoming a director in regulatory affairs. He joined
InterMune in 2002 as senior director regulatory affairs and Connetics in 2005
as vice president of regulatory affairs.
"It's an exciting time to be joining Synosia, with seven clinically
enabled compounds in the pipeline," said Eison, "yet early enough for
regulatory to make important contributions to development strategies that
satisfy regulators, meet the needs of patients and advance the business
interests of Synosia."
Eison earned his bachelor's degree in psychology in 1975 at the State
University of New York at Buffalo and was awarded his doctorate in
physiological psychology/psychopharmacology from UCLA in 1980.
About Synosia Therapeutics
Synosia Therapeutics is a privately-owned, drug development company,
focused on developing new treatments for disorders of the central nervous
system. Its leadership team has over 180 years of combined experience in drug
development. Synosia has offices in Basel, Switzerland, and is headquartered
in South San Francisco, CA. The company was spun out of EuroVentures Inc., a
wholly-owned incubator of Versant Ventures, and recently changed its name from
Synosia Therapeutics has raised $32.5 million funding from Versant
Ventures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures (Menlo
Park, CA) and Novo A/S (Copenhagen, Denmark). For more information, visit
For further information:
For further information: Synosia Therapeutics: In Europe: Julie Walters
at Media Speak, Tel: +44-(0)-1494-753-990, Mobile +44-(0)-775-3626967,
firstname.lastname@example.org; In US: Michele Parisi at Media Speak, Tel: (925)